Results 161 to 170 of about 77,580 (287)

Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis [PDF]

, 2009
OBJECTIVES:\ud To assess, quantify and summarise the cost of illness of rheumatoid arthritis (RA) and ankylosing spondylitis (AS) from the societal perspective.\ud \ud METHODS:\ud Original studies reporting costs of RA or AS were searched systematically.
Ament, A.J.H.A., Boonen, A., Franke, L.C., Laar, M.A.F.J. van de, Severens, J.L.   +4 more
core   +2 more sources

Real‐World Safety Profile of Spesolimab in Generalized Pustular Psoriasis: Insights From Japan as Part of a Multinational Expanded Access Program (EAP)

The Journal of Dermatology, EarlyView.
ABSTRACT Generalized pustular psoriasis (GPP) is a heterogeneous, systemic neutrophilic inflammatory disease, characterized by chronic symptoms and recurrent flares, which can be potentially life‐threatening. Spesolimab, an interleukin‐36 receptor antagonist, has been approved to treat GPP flares in many countries including Japan.
Akimichi Morita, Yayoi Tada, Yuichiro Tsunemi, Mayumi Komine, Takuro Kanekura, Shinichi Imafuku, Toshiya Takahashi, Xuemei Ding, Nichiren Pillai, Morihisa Saitoh, Rafael Sani Simoes, Nora Pöntynen, Keiichi Yamanaka   +12 more
wiley   +1 more source

Comorbidity burden in the first three years after diagnosis in patients with rheumatoid arthritis, psoriatic arthritis or spondyloarthritis: a general practice registry-based study. [PDF]

RMD Open, 2021
Stouten V, Pazmino S, Verschueren P, Mamouris P, Westhovens R, de Vlam K, Bertrand D, Van der Elst K, Vaes B, De Cock D.   +9 more
europepmc   +1 more source

Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure. [PDF]

RMD Open, 2021
Burmester GR, Nash P, Sands BE, Papp K, Stockert L, Jones TV, Tan H, Madsen A, Valdez H, Cohen SB.   +9 more
europepmc   +1 more source

Economic burden of hidradenitis suppurativa based on healthcare resource utilization: German claims data analysis

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Hidradenitis suppurativa (HS) is a chronic, debilitating skin disease affecting approximately 0.1% of the German population. Patients with HS require substantial healthcare resource utilization. This study aimed to assess the economic burden associated with HS in Germany.
Falk G. Bechara, Tanja Tran, Sandeep Kiri, Romy Bley, Kathrin Schlüter, Claudia Grellmann, Sima Melnik, Sylke Schneider‐Burrus   +7 more
wiley   +1 more source

Biologic treatments for psoriasis have different anatomical specificities in residual PASI

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Improved understanding of the immunopathogenesis of psoriasis has led to the development of effective targeted therapies, but patients who respond to treatment without total skin clearance have residual disease. The aim of this study was to demonstrate the existence of specific residual disease (or residual PASI ...
Martina Burlando, Irene Schiavetti, Aurora Parodi, Emanuele Cozzani, Luca Mastorino, Eleonora Bongiovanni, Ilaria Salvi, Martina Del Vecchio, Paolo Dapavo   +8 more
wiley   +1 more source

Impact of adalimumab treatment on impairment of non‐professional activities in psoriasis patients

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Psoriasis can result in reduced quality of life, work productivity loss, and a significant restriction in non‐professional activities. This study investigates the effects of long‐term treatment with adalimumab regarding work ability, non‐professional activities, and health‐related quality of life in a large real‐word ...
Georgios Kokolakis, Sandra Philipp, Thomas Mosch, Björn Fritz, Robert Sabat   +4 more
wiley   +1 more source

PSORIATIC ARTHRITIS [PDF]

Rheumatology, 1984
openaire   +2 more sources

Psoriatic arthritis mutilans [PDF]

QJM: An International Journal of Medicine, 2020
J Samanta, A Chattopadhyay, A Sharma
openaire   +2 more sources

Super‐Response to Guselkumab Treatment in Patients With Moderate‐to‐Severe Psoriasis: Real‐World Data With Up to Five Years of Follow‐Up in The Czech Republic

International Journal of Dermatology, EarlyView.
Super‐response to Guselkumab. ABSTRACT Background Guselkumab, a selective interleukin (IL)‐23 inhibitor, is approved for the treatment of moderate‐to‐severe plaque psoriasis. While randomized clinical trials have introduced the concept of “super‐responders” (SRe)—patients achieving complete skin clearance (Psoriasis Area and Severity Index [PASI] 100 ...
Martina Kojanova, Daniela Pejrilova, Jorga Fialova, Petra Cetkovska, Spyridon Gkalpakiotis, Alena Machovcova, Petr Arenberger, Jiri Stork, Tomas Dolezal, Martin Tichy, the BIOREP study group, Zdenek Antal, Monika Balaz, Jirina Bartonova, Gabriela Behrami, Linda Blahova, Petr Bohac, Martin Cetkovsky, Dominika Diamantova, Magdalena Dobiasova, Olga Filipovska, Jana Foldesova, Martina Grycova, Eduard Hrnciř, Jiri Horazdovsky, Katerina Hrazdirova, Monika Hudymacova, Marie Jandova, Hana Janatova, Lucie Jaresova, Ludmila Kajtmanova, Frantisek Keznikl, Peter Kicko, Zuzana Kondasova, Sarka Kozojedova, Jiri Korda, Jana Kreisslova, Anezka Kreisslova, Silvie Krchova, Lenka Kulmanova, Natalie Kunesova, Zdenka Kysilka, Iva Lomicova, Romana Machackova, Barbora Machackova, Lukas Mericko, Miroslav Necas, Helena Nemcova, Radka Neumannova, Michaela Novakova, Jitka Osmerova, Veronika Pallova, Veronika Patavova, Lucie Petrů, Marie Policarova, Tomas Pospisil, Simona Risianova, Filip Rob, Marcela Rozkosova, Libuse Sazmova, Jaroslav Sevcik, Iva Schmidtmayerova, Martin Sicha, Kristyna Sokolova, Eliska Stankova, Jan Sternbersky, Ivana Strouhalova, David Stuchlik, Alena Stumpfova, Katerina Svarcova, Katerina Tepla, Hana Tomkova, Jana Tresnak Hercogova, Simona Vachatova, Yvetta Vantuchova, Ivana Vejrova, Iva Zampachova   +76 more
wiley   +1 more source